Human medicines European public assessment report (EPAR): Soliris, eculizumab, Date of authorisation: 20/06/2007, Revision: 41, Status: Authorised

Human medicines European public assessment report (EPAR): Fulphila, pegfilgrastim, Date of authorisation: 20/11/2018, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Sibnayal, potassium citrate,potassium hydrogen carbonate, Date of authorisation: 30/04/2021, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Mysimba, naltrexone,bupropion, Date of authorisation: 26/03/2015, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Evfraxy, denosumab, Date of authorisation: 30/06/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Hulio, adalimumab, Date of authorisation: 17/09/2018, Revision: 19, Status: Authorised

Committee for Advanced Therapies (CAT): 18-20 February 2026, European Medicines Agency, Amsterdam, the Netherlands, from 18 February 2026 to 20 February 2026

Agenda of the CAT meeting 18-20 February 2026

European Medicines Regulatory Network (EMRN) workshop on Geographic Atrophy endpoints, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, 29 April 2026

Human medicines European public assessment report (EPAR): Teriflunomide Accord, teriflunomide, Date of authorisation: 09/11/2022, Revision: 4, Status: Authorised